Avastinís Future in FDAís Hands

by Savitha C Muppala on  March 4, 2011 at 3:31 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Avastin, the wonder drug which has been the last resort for many women suffering metastatic breast cancer, risked being disapproved by the FDA last December. Obviously, this is not good news for many advance-stage breast cancer patients.
 Avastinís Future in FDAís Hands
Avastinís Future in FDAís Hands

Nearly 17,500 women rely on Avastin, an advanced stage breast cancer drug that helps reduce blood flow to tumors , thus slowing their growth, and even completely wiping out the tumors in some cases. Therefore, the drug helps women survive much longer.

Avastin is expensive and patients need to spend more than $90,000 a year on treatment.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...